Evidence map›Paper›PMID 23673904›Full record

SynthesisPharmacoEconomics2013

The cost and public health burden of invasive meningococcal disease outbreaks: a systematic review.

Andrea Anonychuk, Gloria Woo, Andrew Vyse, Nadia Demarteau, Andrea C Tricco

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in PharmacoEconomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. [Journal of preventive medicine and hygiene · 2021
    Article
  8. Article
  9. Article
  10. [Health Technology Assessment of meningococcal B vaccine (TrumenbaJournal of preventive medicine and hygiene · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Societal costs due to meningococcal disease: a national registry-based study.ClinicoEconomics and outcomes research : CEOR · 2018
    Article
  15. Article
  16. Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Andrea AnonychukGlaxoSmithKline Vaccines, Wavre, Belgium. andrea.anonychuk@gmail.com
Gloria Woo
Andrew Vyse
Nadia Demarteau
Andrea C Tricco
GlaxoSmithKline (Belgium) · BESt. Michael's Hospital · CAToronto Public Health · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

backgroundInvasive meningococcal disease (IMD) is a serious disease with a rapid onset, high mortality rate, and risk of long-term complications. Numerous reports in the literature conclude that IMD outbreaks are associated with substantial costs to society and significant burden on communities due to the cost associated with the prevention of secondary cases.

objectiveTo systematically review the literature on the costs and public health burden associated with IMD outbreaks.

methodsStudies were primarily identified through searching MEDLINE and EMBASE. Reports were included if they provided cost data related to the containment of an IMD outbreak after 1990 and were written in English, French, or Spanish. Costs were converted to 2010 United States dollars. Outbreaks were categorized by low-income countries (LIC) and high-income countries (HIC) based on gross domestic product per capita. Outbreak containment strategies were classified as small (e.g., targeting members of the school/institution where the outbreak occurred) or large (e.g., targeting everyone in the community).

resultsSixteen articles reporting data on 93 IMD outbreaks fulfilled the eligibility criteria and were included. The majority of outbreaks occurred in HIC. Five studies reported the use of small containment strategies including targeted vaccination and chemoprophylaxis, all occurring in HIC. The average cost per small containment strategy was $299,641 and the average cost per IMD case was $41,857. Eight studies reported large containment strategies involving widespread vaccination targeting a specific age group or community. For HIC, the average cost per large containment strategy was $579,851 and the average cost per IMD case was $55,755. In LIC, the average cost per large containment strategy was $3,407,590 and the average cost per IMD case was $2,222.

conclusionIMD outbreaks were associated with substantial costs. We found that although there were numerous reports on IMD outbreaks, data on containment costs were very limited. More research in this area is warranted.

Indexed as

Health Care CostsChemopreventionCost-Benefit AnalysisDeveloped CountriesDeveloping CountriesDisease OutbreaksHumansMeningococcal InfectionsPublic HealthVaccination

Identifiers

PMID23673904
PMCPMC3691489
OpenAlexW2120799817

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.